Oral complement factor d inhibitors

Patent metadata

Field	Value
Publication number	US-2025275991-A1
Application number	US-202017767798-A
Country	US
Kind code	A1
Filing date	Oct 9, 2020
Priority date	Oct 9, 2019
Publication date	Sep 4, 2025
Grant date	—

Abstract

Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

First claim

1 . A compound of formula (I), or a pharmaceutically acceptable salt thereof:

wherein:
{circle around (A)} is selected from the group consisting of

{circle around (B)} is selected from the group consisting of

 wherein the asterisk (*) indicates the point of attachment to {circle around (C)};

 is selected from the group consisting of

 and
{circle around (C)} is selected from the group consisting of

2 . The compound of claim 1 , wherein {circle around (B)} is

3 . The compound of claim 1 , wherein

is

4 . The compound of claim 1 , wherein {circle around (C)} is selected from the group consisting of

5 . The compound of claim 4 , wherein {circle around (C)} is

6 . A compound of formula (II), or a pharmaceutically acceptable salt thereof:

wherein:
{circle around (A)} is selected from the group consisting of

{circle around (B)} is selected from the group consisting of

 wherein the asterisk (*) indicates the point of attachment to {circle around (C)};

 is selected from the group consisting of

 and
{circle around (C)} is selected from the group consisting of

7 . The compound of claim 6 , wherein {circle around (A)} is

8 . The compound of claim 6 , wherein

is

9 . The compound of claim 6 , wherein {circle around (C)} is selected from the group consisting of

10 . The compound of claim 9 , wherein {circle around (C)} is

11 . A compound of formula (III), or a pharmaceutically acceptable salt thereof:

wherein:
{circle around (A)} is selected from the group consisting of

{circle around (B)} is selected from the group consisting of

 wherein the asterisk (*) indicates the point of attachment to {circle around (C)};

 is selected from the group consisting of

{circle around (C)} is selected from the group consisting of

12 . The compound of claim 11 , wherein {circle around (A)} is

13 . The compound of claim 11 , wherein {circle around (B)} is

14 . The compound of claim 11 , wherein

is

15 . A compound of formula (IV), or a pharmaceutically acceptable salt thereof:

wherein:
{circle around (A)} is selected from the group consisting of

Assignees

• Biocryst Pharm Inc

Inventors

• Kotian Pravin L
• Babu Yarlagadda S
• Zhang Weihe
• Lu peng-cheng
• Spaulding Andrew E
• Wu Minwan
• Lv Wei
• Nguyen Trung Xuan
• Dang zhao
• Raman Krishnan

Classifications

• C07F9/65517

  condensed with carbocyclic rings or carbocyclic ring systems · CPC title

• C07D487/04

  Ortho-condensed systems · CPC title

• C07D417/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D413/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D409/04

  directly linked by a ring-member-to-ring-member bond · CPC title